ClinicalTrials.gg

Program

pacritinib

Also written as “Pacritinib”, “SB1518” and “CYP450 Cocktail and Transporter Substrates with Pacritinib”.

Its studies are mostly in Primary Myelofibrosis · Hematologic Neoplasms · Leukemia, Myelomonocytic, Chronic · COVID-19 · Hodgkin Disease, led by 4 companies.

Furthest: phase 3, since Jan 18, 201318 company-led studies, 3 open or runningNext primary completion: Dec 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Swedish Orphan Biovitrum122 open or runningphase 3since Jan 18, 2013Jan 18, 2013Dec 30, 2026phase 2 · NCT06782373
S*BIO40 open or runningphase 2since Jul 20, 2008Jul 20, 2008none ahead
Takeda10 open or runningphase 2since Oct 21, 2015Oct 21, 2015none ahead
Theradex11 open or runningphase 2since Jun 5, 2025Jun 5, 2025Jul 2028phase 2 · NCT07033598

Also a collaborator on its studies: psi-cro, ppd-development-lp, covance, sgs-s-a and qps-qualitix.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 20, 2008First study: phase 2 study in Leukemia, Myeloid, AcuteNew to S*BIOS*BIO · NCT00719836 · 76 enrolled · United States
  2. Aug 22, 2008Phase 1 study in LymphomaS*BIO · NCT00741871 · 35 enrolled · United States
  3. Sep 2, 2008Phase 2 study in Primary MyelofibrosisS*BIO · NCT00745550 · 55 enrolled · United States, Australia
  4. Dec 16, 2010Phase 2 study in Hodgkin DiseaseS*BIO · NCT01263899 · 28 enrolled · United States, Canada
  5. Jan 18, 2013Swedish Orphan Biovitrum's first study: phase 3 study in Primary MyelofibrosisNew to Swedish Orphan BiovitrumSwedish Orphan Biovitrum · NCT01773187 · 327 enrolled · United States, Australia, Belgium and more
  6. Feb 3, 2014Phase 3 study in Primary MyelofibrosisSwedish Orphan Biovitrum · NCT02055781 · 311 enrolled · United States, Australia, Belgium and more
  7. Oct 21, 2015Takeda's first study: phase 2 study in Primary MyelofibrosisNew to TakedaTakeda · NCT02584777
  8. May 3, 20165 phase 1 studiesSwedish Orphan Biovitrum · NCT02807116, NCT02807077, NCT02807051 and 2 more
  9. May 17, 2017Phase 3 study in Primary MyelofibrosisSwedish Orphan Biovitrum · NCT03165734 · 407 enrolled · United States, Australia, Belarus and more
  10. May 22, 2020Phase 2 study in COVID-19Swedish Orphan Biovitrum · NCT04404361 · 200 enrolled · United States
  11. May 10, 2021Phase 2 study in Primary MyelofibrosisSwedish Orphan Biovitrum · NCT04884191 · 165 enrolled · United States, France, Hungary and more
  12. Dec 12, 2022Phase 1 study in Drug InteractionsSwedish Orphan Biovitrum · NCT05657613 · 60 enrolled · United States
  13. Jan 7, 2025Phase 2 study in VEXAS syndromeSwedish Orphan Biovitrum · NCT06782373 · 156 planned · United States, Canada, France and more
  14. Jun 5, 2025Theradex's first study: phase 2 study in Leukemia, Myelomonocytic, ChronicNew to TheradexTheradex · NCT07033598 · 66 planned · United States, United Kingdom

Ahead

  1. Dec 30, 2026Primary completion: phase 2 study in VEXAS syndromeSwedish Orphan Biovitrum · NCT06782373
  2. Jul 2028Primary completion: phase 2 study in Leukemia, Myelomonocytic, ChronicTheradex · NCT07033598

TargetBeta

“The citrate salt form of pacritinib, an orally bioavailable inhibitor of Janus kinase 2 (JAK2), the JAK2 mutant JAK2V617F and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), ”NCIt, by rule
“Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor”ChEMBL 37, by rule

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07033598Leukemia, Myelomonocytic, Chronic · United States, United Kingdom2RecruitingTheradexJul 202866
NCT06782373VEXAS syndrome · United States, Canada, France and more2RecruitingSwedish Orphan BiovitrumDec 30, 2026156
NCT05657613Drug Interactions · United States1CompletedSwedish Orphan BiovitrumJun 8, 202360
NCT04884191Primary Myelofibrosis · United States, France, Hungary and more2CompletedSwedish Orphan BiovitrumSep 4, 2019165
NCT04404361COVID-19 · United States2TerminatedSwedish Orphan BiovitrumSep 21, 2021200
NCT03165734Primary Myelofibrosis · United States, Australia, Belarus and more3Active, not recruitingSwedish Orphan BiovitrumOct 5, 2026407
NCT02807116Healthy Subjects · United States1CompletedSwedish Orphan BiovitrumFeb 201518
NCT02807077Primary Myelofibrosis · Germany, Moldova, Republic of, Romania1CompletedSwedish Orphan BiovitrumJul 201540
NCT02807051Drug Interaction Study · United States1CompletedSwedish Orphan BiovitrumOct 201420
NCT02803762Healthy · Netherlands1CompletedSwedish Orphan BiovitrumOct 20146
NCT02765724Primary Myelofibrosis · Germany, Moldova, Republic of1CompletedSwedish Orphan BiovitrumJun 201528
NCT02584777Primary Myelofibrosis2WithdrawnTakedaSep 30, 20170
NCT02055781Primary Myelofibrosis · United States, Australia, Belgium and more3TerminatedSwedish Orphan BiovitrumApr 2016311
NCT01773187Primary Myelofibrosis · United States, Australia, Belgium and more3TerminatedSwedish Orphan BiovitrumJan 2015327
NCT01263899Hodgkin Disease · United States, Canada2CompletedS*BIOFeb 201228
NCT00745550Primary Myelofibrosis · United States, Australia2CompletedS*BIOJan 201255
NCT00741871Lymphoma · United States1CompletedS*BIOOct 201135
NCT00719836Leukemia, Myeloid, Acute · United States2CompletedS*BIOJan 201276

How it is read

Names in the registry

  • “Pacritinib”, 13 entries
  • “SB1518”, 4 entries
  • “CYP450 Cocktail and Transporter Substrates with Pacritinib”, 1 entry
  • “Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib”, 1 entry
  • “Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.